2016 Fiscal Year Final Research Report
MUC21 glycoforms as the target of cancer diagnosis and therapy
| Project/Area Number |
25293011
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Partial Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Biological pharmacy
|
|---|
| Research Institution | Juntendo University (2016)
St. Luke's International University (2014-2015)
The University of Tokyo (2013) |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
伝田 香里 順天堂大学, 医学部, 助教 (00313122)
|
|---|
| Project Period (FY) |
2013-04-01 – 2017-03-31
|
| Keywords | ムチン / 乳腺がん / 治療抵抗性 / モノクローナル抗体 / グライコフォーム / MUC21 |
|---|
| Outline of Final Research Achievements |
Expression of MUC21 gene and its glycosylated gene products was examined with breast carcinoma cells and tissue specimens with a variety of subtypes. It was found that MUC21 expression was associated with poor therapeutic outcomes among triple negative breast carcinoma patients but whether any association with the expression of particular glycoform of MUC21 is still unknown. An experimental system to investigate the contribution of interaction between MUC21 and galectin 3 in modulating apoptotic pathways was successfully established.
|
| Free Research Field |
腫瘍学、免疫学、糖鎖生物学
|
